Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE)

, ceritinib and brigatinib are second-generation ITK-ALK. They have been shown to be effective in the first line of treatment in randomized trials. Alectinib has shown superiority to crizotinib as the first

  • 0 views
  • 29 Apr, 2022
  • 30 locations
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3)

Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this study, participants will be people with non

  • 21 views
  • 26 Apr, 2022
  • 94 locations
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

brigatinib monotherapy (Arm A) or brigatinib and carboplatin-pemetrexed therapy (Arm B). An estimated 110 patients (55 in Arm A, 55 in Arm B) will be enrolled at approximately 30 centers. A safety phase will

brigatinib
pemetrexed
lipase
serum bilirubin level
kidney function test
  • 0 views
  • 04 Oct, 2022
  • 1 location
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

This is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK

metastasis
brigatinib
lipase
cancer chemotherapy
kinase inhibitor
  • 0 views
  • 27 Apr, 2022
  • 21 locations
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

This is single-arm, open-label study design. Patients will receive brigatinib until disease progression, unacceptable toxicity, withdrawal of consent, of death.

alopecia
metastasis
brigatinib
serum bilirubin level
lipase
  • 1 views
  • 21 Apr, 2022
  • 1 location
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

This phase Ib trial studies the side effects and best dose of brigatinib and how well it works with bevacizumab in treating patients with ALK-rearranged non-small cell lung cancer that has

periodic abstinence
leptomeningeal disease
metastasis
lung cancer
brigatinib
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase I/II Study of Brigatinib in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors (Briga-PED)

This is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL

  • 0 views
  • 10 Oct, 2022
  • 2 locations
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2)

: Brigatinib

brigatinib
cataract
nf2 gene
experimental drug
investigational drug
  • 40 views
  • 30 Jun, 2022
  • 6 locations
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will determine the RP2D and, if applicable, the …

  • 0 views
  • 28 Oct, 2022
  • 4 locations
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

BioEXALK is a prospective study evaluating the biological characteristics of advanced ALK-rearranged NSCLC treated with next generation TKIs in first line, included in the national EXPLORE ALK cohort (GFPC 03-2019), a non-interventional, national, multi-center cohort of ALK-rearranged NSCLC patients. BioExALK study will be proposed to every patient included in the …

  • 0 views
  • 26 Nov, 2021
  • 45 locations